Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan in ADPKD (TEMPO 4/4)
NCT01214421Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2010
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Percent Change From Baseline in Total Kidney Volume at 24 months. Started May 2010; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT01214421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01214421.